The Future of the CRA: Perspectives from Clinical Operations Leaders Across the Industry
Featuring leaders from AstraZeneca, Boehringer Ingelheim Pharmaceuticals Inc., IPSEN, and a biopharmaceutical executive with experience across Merck, Sanofi, and Johnson & Johnson
INSPIRE. CONNECT. INNOVATE.
On-Demand Webinar
The CRA Talent and Skill Evolution: From Oversight to Enablement, From Fact Checker to Strategic Partner
As clinical trials become more complex, decentralized and data-driven, the Clinical Research Associate is evolving from monitor and fact checker to strategic site partner, risk navigator and delivery enabler. Today, CRA success is no longer measured solely by visit volume or pages verified alone. Their impact is increasingly defined by how effectively they strengthen site relationships, anticipate operational challenges, support recruitment and retention, interpret risk signals and improve trial quality. This whitepaper explores what this evolution means for clinical operations leaders, sponsors and talent strategists.
In this paper you’ll learn:
How leading sponsors are redefining CRA success
What workforce trends mean for future trial delivery
Why skills-based hiring may unlock hidden talent pools
How organizations can avoid future workforce pipeline challenges
What capabilities tomorrow’s CRA will need to succeed
Whitepaper Participants
Karen Correa, PhD
VP, US CDO Boehringer Ingelheim Pharmaceuticals, Inc.
Nick Hodges
Senior Vice President Head of Clinical Development Operations IPSEN
David Carruthers
Vice President Clinical Operations AstraZeneca
Mark Travers, PhD, MBA
Biopharmaceutical Leader Former Merck, Sanofi & JnJ Executive
Diana Cucos, PhD
Global Head, FSP 360 & Modular Solutions Syneos Health